In-Vivo Cell Therapy Intelligence Report, Q3 2026

This report maps the global in-vivo cell therapy competitive landscape across 332 active programs as of Q3 2026, with 258 preclinical and only one Phase 2 trial. CAR-T accounts for 74% of programs, following the ex-vivo playbook into an off-the-shelf format. China and the US split the field nearly evenly at 161 and 141 programs, though China holds the only program past Phase 1.

The delivery architecture divides between two co-leading vehicles: integrating lentiviral (107 programs, 32%) built around durability, and transient LNP-mRNA/circRNA (101 programs, 30%) built around tolerability and tunability. Lentiviral tilts toward oncology while RNA tilts toward autoimmune, reflecting the different expression profiles each indication demands. CD19 and BCMA concentrate the near-term field, mirroring ex-vivo precedent, while multi-target and solid-tumor entries mark the open ground away from validated biology.

Deal value has climbed ahead of clinical validation, reaching $12B in total disclosed value in 2026 YTD. Lilly marked the largest commitment with Kelonia (up to $7B, viral) and Orna (up to $2.4B, RNA), taking both delivery architectures. Early human data have landed on both arms: HN2301 drove complete B-cell depletion in SLE, and KLN-1010 achieved 100% MRD-negative responses in myeloma. The value case against ex-vivo CAR-T centers on off-the-shelf supply, lymphodepletion-free dosing, and outpatient administration, though T-cell fitness in pretreated patients and off-target tropism control remain open questions. Looking ahead, we expect the field to further bifurcate by indication, with autoimmune favoring transient RNA and oncology requiring durable integrating constructs, while B-cell and immunology franchise owners continue buying in.